Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Income from Continuing Operations came in at 13091000.0 in Q1 2026, up 42.19% YoY from 9206839.27 in Q1 2025, and down 9.66% on a QoQ basis from 11938000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Income from Continuing Operations data on file, last reported at 13091000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 42.19% year-over-year to 13091000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61984000.0 (up 35.71% YoY) and the FY2025 annual result came in at 81889000.0, up 29.43% from the prior year.
- Income from Continuing Operations slipped to 13091000.0 in Q1 2026, from 11938000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11938000.0 in Q4 2025 to a low of 39065000.0 in Q2 2023.
- A 5-year average of 26229235.29 and a median of 26348000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 67.83% in 2022, down 31.95% in 2022.
- Tracing ENTA's Income from Continuing Operations over 5 years: stood at 28986000.0 in 2022, then decreased by 15.25% to 33407000.0 in 2023, then surged by 33.28% to 22290000.0 in 2024, then surged by 46.44% to 11938000.0 in 2025, then slipped by 9.66% to 13091000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 13091000.0 (Q1 2026), 11938000.0 (Q4 2025), and 18700000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -19.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.50 Mn |
| Mar 31, 2026 | -13.09 Mn |
| Dec 31, 2025 | -11.94 Mn |
| Sep 30, 2025 | -18.70 Mn |
| Jun 30, 2025 | -18.26 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -22.29 Mn |
| Sep 30, 2024 | -28.82 Mn |
| Jun 30, 2024 | -22.66 Mn |
| Mar 31, 2024 | -31.16 Mn |
| Dec 31, 2023 | -33.41 Mn |
| Sep 30, 2023 | -25.59 Mn |
| Jun 30, 2023 | -39.07 Mn |
| Mar 31, 2023 | -37.66 Mn |
| Dec 31, 2022 | -28.99 Mn |
| Sep 30, 2022 | -26.35 Mn |
| Jun 30, 2022 | -31.70 Mn |
| Mar 31, 2022 | -33.59 Mn |
| Dec 31, 2021 | -30.12 Mn |
| Sep 30, 2021 | -81.90 Mn |